Quantitative proteomics for molecular diagnostics of public health: the quest for biomarkers of infectious disease

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Proteomics is well established within clinical analysis with a range of biomarkers recognised by the FDA, most of these are biomarkers of cancer [1]. Analysis of prostate specific antigen (PSA) in serum is now a routine part of prostate cancer diagnosis, where it is used alongside digital examination to determine the need for invasive prostate biopsies. The use of proteomics for investigating public health has been reported [2], where the inflammation biomarker C-reactive protein (CRP) was quantified in the urine of ~8600 study participants (10% of surveyed population) using nephelometry. Whilst an excellent study it required the analysis of approximately 58,000 urine and 8600 serum samples, where as if the same study was performed using wastewater a single representative sample could have been collected for the whole population. Analysis of pharmaceuticals and drugs of abuse as part of wastewater-based epidemiology (WWBE) is becoming well established [3], however there is still scope for expansion particularly into examining the relationship between public health and disease. We have developed a method for the analysis of proteins of disease using liquid chromatography coupled with mass spectrometry, using instruments similar to those already used for the analysis of small molecule biomarkers in WWBE [3]. To allow for this the protein biomarkers are initially digested using enzymes to form peptides, which are characteristic for their respective proteins. These characteristic peptides are then analysed using hydrophilic interaction liquid chromatography and either a triple quadrupole or quadrupole-time of flight instrument, with the dual instrument approach allowing for both biomarker quantification and for future retrospective biomarker analysis. The current analytical focus is on clinically recognised proteins of either general health, mainly inflammation, or proteins of cancer, focussing on prostate cancer. By pursuing this methodology we hope to achieve broad applicability with techniques currently used for the analysis of small molecules, and allow for easy uptake of protein analysis within the wider WWBE community.

1. Fuzery, A.K., et al., Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clinical proteomics, 2013. 10(1): p. 13-13. 2. Stuveling, E.M., et al., C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney International, 2003. 63(2): p. 654-661. 3. Ort, C., et al., Spatial differences and temporal changes in illicit drug use in Europe quantified by wastewater analysis. Addiction, 2014. 109(8): p. 1338-1352.
Original languageEnglish
Title of host publicationTesting the waters 2017, Wastewater-based epidemiology: current applications and future perspectives, 3rd international conference
Publication statusPublished - 2017
EventTesting the Waters 2017: 3rd International Conference on Wastewater-based Epidermology - Lisbon Congress Centre , Lisbon , Portugal
Duration: 26 Oct 201727 Oct 2017
http://score-cost.eu/network-activities/meetings/ttw2017/

Conference

ConferenceTesting the Waters 2017: 3rd International Conference on Wastewater-based Epidermology
CountryPortugal
CityLisbon
Period26/10/1727/10/17
Internet address

Fingerprint

Molecular Pathology
Proteomics
Communicable Diseases
Public Health
Biomarkers
Waste Water
Street Drugs
Epidemiology
Proteins
Liquid Chromatography
C-Reactive Protein
Prostatic Neoplasms
Urine
Population
Nephelometry and Turbidimetry
Inflammation
Kidney
Peptides
Prostate-Specific Antigen
Tumor Biomarkers

Cite this

Rice, J., Kasprzyk-Hordern, B., & Lubben, A. (2017). Quantitative proteomics for molecular diagnostics of public health: the quest for biomarkers of infectious disease. In Testing the waters 2017, Wastewater-based epidemiology: current applications and future perspectives, 3rd international conference

Quantitative proteomics for molecular diagnostics of public health: the quest for biomarkers of infectious disease. / Rice, Jack; Kasprzyk-Hordern, Barbara; Lubben, Anneke.

Testing the waters 2017, Wastewater-based epidemiology: current applications and future perspectives, 3rd international conference. 2017.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Rice, J, Kasprzyk-Hordern, B & Lubben, A 2017, Quantitative proteomics for molecular diagnostics of public health: the quest for biomarkers of infectious disease. in Testing the waters 2017, Wastewater-based epidemiology: current applications and future perspectives, 3rd international conference. Testing the Waters 2017: 3rd International Conference on Wastewater-based Epidermology , Lisbon , Portugal, 26/10/17.
Rice J, Kasprzyk-Hordern B, Lubben A. Quantitative proteomics for molecular diagnostics of public health: the quest for biomarkers of infectious disease. In Testing the waters 2017, Wastewater-based epidemiology: current applications and future perspectives, 3rd international conference. 2017
Rice, Jack ; Kasprzyk-Hordern, Barbara ; Lubben, Anneke. / Quantitative proteomics for molecular diagnostics of public health: the quest for biomarkers of infectious disease. Testing the waters 2017, Wastewater-based epidemiology: current applications and future perspectives, 3rd international conference. 2017.
@inproceedings{1b49a9a37b6c4b618f47c0e03e463571,
title = "Quantitative proteomics for molecular diagnostics of public health: the quest for biomarkers of infectious disease",
abstract = "Proteomics is well established within clinical analysis with a range of biomarkers recognised by the FDA, most of these are biomarkers of cancer [1]. Analysis of prostate specific antigen (PSA) in serum is now a routine part of prostate cancer diagnosis, where it is used alongside digital examination to determine the need for invasive prostate biopsies. The use of proteomics for investigating public health has been reported [2], where the inflammation biomarker C-reactive protein (CRP) was quantified in the urine of ~8600 study participants (10{\%} of surveyed population) using nephelometry. Whilst an excellent study it required the analysis of approximately 58,000 urine and 8600 serum samples, where as if the same study was performed using wastewater a single representative sample could have been collected for the whole population. Analysis of pharmaceuticals and drugs of abuse as part of wastewater-based epidemiology (WWBE) is becoming well established [3], however there is still scope for expansion particularly into examining the relationship between public health and disease. We have developed a method for the analysis of proteins of disease using liquid chromatography coupled with mass spectrometry, using instruments similar to those already used for the analysis of small molecule biomarkers in WWBE [3]. To allow for this the protein biomarkers are initially digested using enzymes to form peptides, which are characteristic for their respective proteins. These characteristic peptides are then analysed using hydrophilic interaction liquid chromatography and either a triple quadrupole or quadrupole-time of flight instrument, with the dual instrument approach allowing for both biomarker quantification and for future retrospective biomarker analysis. The current analytical focus is on clinically recognised proteins of either general health, mainly inflammation, or proteins of cancer, focussing on prostate cancer. By pursuing this methodology we hope to achieve broad applicability with techniques currently used for the analysis of small molecules, and allow for easy uptake of protein analysis within the wider WWBE community. 1. Fuzery, A.K., et al., Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clinical proteomics, 2013. 10(1): p. 13-13. 2. Stuveling, E.M., et al., C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney International, 2003. 63(2): p. 654-661. 3. Ort, C., et al., Spatial differences and temporal changes in illicit drug use in Europe quantified by wastewater analysis. Addiction, 2014. 109(8): p. 1338-1352.",
author = "Jack Rice and Barbara Kasprzyk-Hordern and Anneke Lubben",
year = "2017",
language = "English",
booktitle = "Testing the waters 2017, Wastewater-based epidemiology: current applications and future perspectives, 3rd international conference",

}

TY - GEN

T1 - Quantitative proteomics for molecular diagnostics of public health: the quest for biomarkers of infectious disease

AU - Rice, Jack

AU - Kasprzyk-Hordern, Barbara

AU - Lubben, Anneke

PY - 2017

Y1 - 2017

N2 - Proteomics is well established within clinical analysis with a range of biomarkers recognised by the FDA, most of these are biomarkers of cancer [1]. Analysis of prostate specific antigen (PSA) in serum is now a routine part of prostate cancer diagnosis, where it is used alongside digital examination to determine the need for invasive prostate biopsies. The use of proteomics for investigating public health has been reported [2], where the inflammation biomarker C-reactive protein (CRP) was quantified in the urine of ~8600 study participants (10% of surveyed population) using nephelometry. Whilst an excellent study it required the analysis of approximately 58,000 urine and 8600 serum samples, where as if the same study was performed using wastewater a single representative sample could have been collected for the whole population. Analysis of pharmaceuticals and drugs of abuse as part of wastewater-based epidemiology (WWBE) is becoming well established [3], however there is still scope for expansion particularly into examining the relationship between public health and disease. We have developed a method for the analysis of proteins of disease using liquid chromatography coupled with mass spectrometry, using instruments similar to those already used for the analysis of small molecule biomarkers in WWBE [3]. To allow for this the protein biomarkers are initially digested using enzymes to form peptides, which are characteristic for their respective proteins. These characteristic peptides are then analysed using hydrophilic interaction liquid chromatography and either a triple quadrupole or quadrupole-time of flight instrument, with the dual instrument approach allowing for both biomarker quantification and for future retrospective biomarker analysis. The current analytical focus is on clinically recognised proteins of either general health, mainly inflammation, or proteins of cancer, focussing on prostate cancer. By pursuing this methodology we hope to achieve broad applicability with techniques currently used for the analysis of small molecules, and allow for easy uptake of protein analysis within the wider WWBE community. 1. Fuzery, A.K., et al., Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clinical proteomics, 2013. 10(1): p. 13-13. 2. Stuveling, E.M., et al., C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney International, 2003. 63(2): p. 654-661. 3. Ort, C., et al., Spatial differences and temporal changes in illicit drug use in Europe quantified by wastewater analysis. Addiction, 2014. 109(8): p. 1338-1352.

AB - Proteomics is well established within clinical analysis with a range of biomarkers recognised by the FDA, most of these are biomarkers of cancer [1]. Analysis of prostate specific antigen (PSA) in serum is now a routine part of prostate cancer diagnosis, where it is used alongside digital examination to determine the need for invasive prostate biopsies. The use of proteomics for investigating public health has been reported [2], where the inflammation biomarker C-reactive protein (CRP) was quantified in the urine of ~8600 study participants (10% of surveyed population) using nephelometry. Whilst an excellent study it required the analysis of approximately 58,000 urine and 8600 serum samples, where as if the same study was performed using wastewater a single representative sample could have been collected for the whole population. Analysis of pharmaceuticals and drugs of abuse as part of wastewater-based epidemiology (WWBE) is becoming well established [3], however there is still scope for expansion particularly into examining the relationship between public health and disease. We have developed a method for the analysis of proteins of disease using liquid chromatography coupled with mass spectrometry, using instruments similar to those already used for the analysis of small molecule biomarkers in WWBE [3]. To allow for this the protein biomarkers are initially digested using enzymes to form peptides, which are characteristic for their respective proteins. These characteristic peptides are then analysed using hydrophilic interaction liquid chromatography and either a triple quadrupole or quadrupole-time of flight instrument, with the dual instrument approach allowing for both biomarker quantification and for future retrospective biomarker analysis. The current analytical focus is on clinically recognised proteins of either general health, mainly inflammation, or proteins of cancer, focussing on prostate cancer. By pursuing this methodology we hope to achieve broad applicability with techniques currently used for the analysis of small molecules, and allow for easy uptake of protein analysis within the wider WWBE community. 1. Fuzery, A.K., et al., Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clinical proteomics, 2013. 10(1): p. 13-13. 2. Stuveling, E.M., et al., C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney International, 2003. 63(2): p. 654-661. 3. Ort, C., et al., Spatial differences and temporal changes in illicit drug use in Europe quantified by wastewater analysis. Addiction, 2014. 109(8): p. 1338-1352.

M3 - Conference contribution

BT - Testing the waters 2017, Wastewater-based epidemiology: current applications and future perspectives, 3rd international conference

ER -